Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA‐Labeled Dosing Frequency of RHB‐105 Low‐Dose Rifabutin Triple Therapy for Helicobacter pylori Eradication
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.6178 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Nimish Vakil und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. Hauptthemen laut MEDLINE: Rifabutin, Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSRD VA.
Abstract (Originalsprache)
Patient adherence is vital for Helicobacter pylori eradication. Simplifying therapy dosing schedules may promote patient adherence, enhance treatment success rates, and help mitigate the development of antibiotic resistance. We aimed to assess plasma and intragastric rifabutin, amoxicillin, and omeprazole concentrations comparing two dosing schedules of RHB‐105 (every 8 h and a more flexible three‐times daily schedule, at 8 a.m., 12 p.m., and 6 p.m.) using a validated physiologically based pharmacokinetic (PBPK) model. Leveraging in vitro and in vivo information on the pharmacokinetics of the three components of RHB‐105, we developed mechanistic absorption PBPK models to predict plasma and intragastric concentration–time profiles for each component. There were only negligible differences in the area under the concentration–time curves (AUC) for plasma and the intragastric compartment, and maximal concentration (C max ) with only up to a 1.1‐fold difference for rifabutin, amoxicillin, and omeprazole between dosing schedules. Overlapping 90% confidence intervals for both AUC and C max support that overall exposures are comparable regardless of dosing every 8 h or three‐times daily for all three drugs. Drug exposure was highly similar for rifabutin, amoxicillin, and omeprazole with each dosing schedule. Novel mechanistic absorption PBPK modeling supports the approval and use of the more flexible dosing schedule for RHB‐105, simplifying patient experience and potentially increasing adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
- College of Medicine, University of Tennessee, Memphis, TN, USA.
- Division of Gastroenterology, University of California, San Diego, CA, USA.
- Certara, Simcyp Division, Sheffield, UK.
- Certara, Integrated Drug Development, Montreal, Quebec, Canada.
- RedHill Biopharma, Medical Affairs, Raleigh, NC, USA.
ORCID-Profile: Nimish Vakil, Colin W Howden, Shailja C Shah, Kuan-Fu Chen, Elliot Offman, June S Almenoff, Kely L Sheldon
Förderung
- CSRD VA
Zitieren
APA
Vakil, N., Howden, C. W., Shah, S. C., Chen, K. F., Offman, E., Almenoff, J. S., & Sheldon, K. L. (2025). Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA‐Labeled Dosing Frequency of RHB‐105 Low‐Dose Rifabutin Triple Therapy for Helicobacter pylori Eradication. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6178
Vancouver
Vakil N, Howden CW, Shah SC, Chen KF, Offman E, Almenoff JS, et al. Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA‐Labeled Dosing Frequency of RHB‐105 Low‐Dose Rifabutin Triple Therapy for Helicobacter pylori Eradication. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6178
BibTeX
@article{Vakil2025,
author = {Vakil, Nimish and Howden, Colin W and Shah, Shailja C and Chen, Kuan-Fu and Offman, Elliot and Almenoff, June S and Sheldon, Kely L},
title = {Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA‐Labeled Dosing Frequency of RHB‐105 Low‐Dose Rifabutin Triple Therapy for Helicobacter pylori Eradication},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.6178}
}
EUVIMED